Document is current

Article History

Received: 25 May 2021

Accepted: 9 November 2021

First Online: 3 January 2022

Declarations

:

: All trials were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines. FINCH 1 was approved by the Advarra Central Institutional Review Board (Reference # 00000971). FINCH 2 was approved by the Administrative Panel on Human Subjects in Medical Research (Reference # 4593). FINCH 3 was approved by Ethics Committee Research UZ/KU Leuven (Reference # S59627). The study protocols were approved by the international review board or ethics committee at each study site, and all patients provided written informed consent.

: Not applicable.

: COB reports grant/research support from BMS; is a consultant for AbbVie; BMS; Eli Lilly & Co.; Gilead Sciences, Inc.; Janssen; Pfizer; Regeneron; and Sanofi. DW has financial ties with Eli Lilly & Co.; Gilead Sciences, Inc.; Pfizer; and Roche. PN reports financial relationships with AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly & Co., Gilead, Janssen, MSD, Novartis, Pfizer, Roche, and Sanofi. SJL, LY, and HH are employees and shareholders of Gilead Sciences, Inc. JMK is an employee of Galapagos NV. BC receives grant/research support from Novartis, Pfizer, and Roche-Chugai; is a consultant for AbbVie; Celltrion; Eli Lilly & Co.; Galapagos; Gilead Sciences, Inc.; Janssen; Roche-Chugai; and is on the speakers bureau for BMS; Eli Lilly & Co.; Gilead Sciences, Inc.; MSD; Pfizer; Roche-Chugai.